Trial Profile

A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma in the United Kingdom (UK)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms CERES
Sponsors Ipsen

Most Recent Events

21 Sep 2020 Results of post-hoc analyses assessing clinical outcomes (overall survival and progression free survival) presented at the 45th European Society for Medical Oncology Congress
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
23 Aug 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com